Cinitapride

Cinitapride is a 5-HT1 and 5-HT4 receptors Agonist and 5-HT2 receptors Antagonist belonging to Antiemetic agent.

Cinitapride is a benzamide with gastroprokinetic and antiemetic properties typically used for the treatment of gastrointestinal motility disorders such as gastro esophageal reflux disease (GERD), non-ulcer dyspepsia, and delayed gastric emptying.

The maximum plasma levels are reached two hours after the oral administration of Cinitapride. Its elimination half-life is 3 to 5 hours for the first 8 hours, with a residual half-life of over 15 hours with extremely low plasma levels after that time.

Cinitapride shows side effects like Headache, Nausea, Drowsiness, Diarrhea, Involuntary muscular movements of the head, neck, and tongue, rarely eruptions, itching or allergic reactions.

Cinitapride is available in the form of Oral tablet.

Cinitaprideis available in India, Mexico, Canada, China,and Japan.

Cinitapride belongs to the Antiemetic agent acts as a 5-HT1 and 5-HT4 receptors Agonist and 5-HT2 receptors Antagonist.

Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.Cinitapride works by increasing the concentration of a chemical known as acetylcholine that helps in increasing the contractions of the stomach muscles.

The Data of Onset and Duration of action of Cinitaprideis not clinically established.

The Tmax of Cinitapride is approximately 2 hours.

Cinitapride is available in the form of Oral Tablet.

Cinitapride tablet taken orally usually thrice a day, 15 minutes before meals.

Cinitapride is a medicine used to increase the movement of food in your stomach and intestine. It is used to treat Gastro esophageal reflux disease (a condition in which stomach acid flows back into the food pipe, causing heartburn and discomfort), indigestion, and gastroparesis (delayed stomach emptying).

Cinitapride is a 5-HT1 and 5-HT4 receptors Agonist and 5-HT2 receptors Antagonist belonging to Antiemetic agent.

Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.

It works by increasing the production of a chemical messenger that improves the motility of your stomach and intestine. This enhances the movement of food in your body.

Cinitapride is approved for use in the following clinical indications

• Gastrointestinal disorders

It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.

• Gastrointestinal disorders

The usual daily dosage for adults is 1mg orally thrice a day, 15 minutes before meals.

Cinitapride is available in various strengths as 1mg.

Cinitapride is available in the form of Oral Tablet.

• Dosage Adjustment in Kidney Patient

Caution is taken if suffering from kidney impairment.

• Dosage Adjustment in Hepatic impairment Patient

Caution is taken if suffering from liver impairment.

Cinitapride is contraindicated in patients with

• If allergic to Cinitapride or similar medicines
• Suffering from a neurological disorder i.e. tardive dyskinesia (a condition characterised by repetitive involuntary movements).
• Suffering from or ever had a history of bleeding in the stomach and intestine
• Suffering from holes in the walls of the stomach and intestine (gastrointestinal perforation).
• Suffering from complete or partial blockage in the intestine.

• Caution should be exercised in patients with history of gastrointestinalbleeding, mechanical obstruction or perforation, movement disorder, during pregnancy and breastfeeding.
• Avoid alcohol consumption.
• It may cause drowsiness, do not drive a car, or operate machinery while taking this medication.

Avoid alcohol consumption while taking Cinitapride. It may lead to excessive drowsiness.

Avoid taking Cinitapride if you are breastfeeding as it is unknown if the Cinitapride passes into your breastmilk.

The safety of Cinitapride in pregnant women has not yet been determined. It is not advised to take Cinitapride during pregnancy until it is considered potential risks.

There are no interactions with food found/ established.

Common

Headache, Nausea, Drowsiness, Diarrhea, Involuntary muscular movements of the head, neck and tongue, rarely eruptions, itching or allergic reactions.

• Phenothiazine:

Cinitapride can potentiate the effect of phenothiazine and other anti-dopaminergic drugs on the CNS.

• Digoxin:

Cinitapride can reduce the effect of digoxin by reducing its absorption.

The common side effects of Cinitapride include the following

Common side effects

Headache, Nausea, Drowsiness, Diarrhea, Involuntary muscular movements of the head, neck, and tongue, rarely eruptions, itching or allergic reactions.

• Pregnancy

Pregnancy Category

The safety of Cinitapride in pregnant women has not yet been determined. It is not advised to take Cinitapride during pregnancy until it is considered potential risks.

• Nursing Mothers  

Avoid taking Cinitapride if you are breastfeeding as it is unknown if the Cinitapride passes into your breastmilk.

• Pediatric Use

Cinitapride should not be given to children as safety and effectiveness were not established.

Pharmacodynamics

Information is not available.

Pharmacokinetics

• Absorption

The maximum plasma levels are reached two hours after the oral administration of Cinitapride.

• Distribution

Information is not available.

• Metabolism and Excretion

Its elimination half-life is 3 to 5 hours for the first 8 hours, with a residual half-life of over 15 hours with extremely low plasma levels after that time.

• https://go.drugbank.com/drugs/DB08810
• https://www.drugs.com/international/cinitapride.html
• https://www.practo.com/medicine-info/cinitapride-1111-api
• https://www.mims.com/india/drug/info/cintodac